Literature DB >> 16260913

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.

Julie A Sheldon1, Angélica Corral, Berta Rodés, Stefan Mauss, Juergen Rockstroh, Florian Berger, Carolynne Schwarze-Zander, Vincent Soriano.   

Abstract

Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed. Using bulk population sequencing and a sensitive limiting dilution analysis, the selection of K65R or other resistance mutations did not occur in HIV, suggesting that adefovir can be confidently used as hepatitis B virus (HBV) therapy in HIV/HBV-co-infected patients who do not require antiretroviral therapy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16260913     DOI： 10.1097/01.aids.0000189563.79976.05

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  11 in total

1.  Management of HIV/HBV coinfection.

Authors:  Andy O Miller
Journal:  MedGenMed       Date:  2006-02-07

2.  Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

Authors:  Marion G Peters; Janet Andersen; Patrick Lynch; Tun Liu; Beverly Alston-Smith; Carol L Brosgart; Jeffrey M Jacobson; Victoria A Johnson; Richard B Pollard; James F Rooney; Kenneth E Sherman; Susan Swindells; Bruce Polsky
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

3.  Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice.

Authors:  Nezam H Afdhal; Bruce R Bacon; Robert S Brown
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-03

4.  Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.

Authors:  Kai Lin; Sylwia Karwowska; Eric Lam; Kay Limoli; Thomas G Evans; Claudio Avila
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

5.  Hepatitis B in HIV: available treatment options and approach to therapy.

Authors:  Melissa Osborn
Journal:  Curr Infect Dis Rep       Date:  2009-09       Impact factor: 3.725

6.  HIV and Hepatitis B Virus Coinfection: Approach to Management: Case Study and Commentary.

Authors:  Rachel Chasan; Lindsey Reese; Dawn Fishbein
Journal:  J Clin Outcomes Manag       Date:  2010-06-01

Review 7.  Management of hepatitis B virus co-infection on and off antiretroviral therapy.

Authors:  Vincent Soriano; Eugenia Vispo; Marcelle Bottecchia; Julie Sheldon; Paula Tuma; Javier Garcia-Samaniego; Pablo Barreiro
Journal:  Curr HIV/AIDS Rep       Date:  2008-05       Impact factor: 5.071

8.  Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.

Authors:  Karine Lacombe; Joël Gozlan; Anders Boyd; Pierre-Yves Boelle; Philippe Bonnard; Jean-Michel Molina; Patrick Miailhes; Caroline Lascoux-Combe; Lawrence Serfaty; Fabien Zoulim; Pierre-Marie Girard
Journal:  Antivir Ther       Date:  2008

9.  Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.

Authors:  Marina B Klein; Jean-Guy Baril; Marc-André Charron; Claude Fortin; Richard Lalonde; Marie-France Matte; Marc Poliquin; Annie Talbot; Rachel Therrien; Cécile Tremblay; Benoît Trottier; Irina Tsarevsky; Jean-Pierre Villeneuve
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

10.  Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.

Authors:  Gregory J Dore; Vicente Soriano; Jürgen Rockstroh; Bernd Kupfer; Ellen Tedaldi; Lars Peters; Jacqueline Neuhaus; Massimo Puoti; Marina B Klein; Amanda Mocroft; Bonaventura Clotet; Jens D Lundgren
Journal:  AIDS       Date:  2010-03-27       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.